US-based private equity investment firm Versa Capital Management has acquired medical technology company SynCardia Systems as part of the latter's previously announced reorganisation process.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

SynCardia is the developer of the temporary Total Artificial Heart (TAH-t) which is an implantable system designed to treat a failed heart in patients suffering from end-stage biventricular (both sides) heart failure.

Similar to a donor heart transplant, the SynCardia Total Artificial Heart replaces the native heart’s two failed ventricles and four valves thereby resulting inhe elimination of the source of end-stage biventricular heart failure.

It results in immediate and safe blood flow of up to 9.5l per minute through each ventricle.

The high-blood volume accelerates the recovery of vital organs.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The SynCardia TAH-t has been used to conduct more than 1,635 implants while accounting for 560 patient years of life.

SynCardia will remain headquartered in Tucson, Arizona and will be led by president and CEO Michael Garippa.

"The SynCardia Total Artificial Heart replaces the native heart’s two failed ventricles and four valves thereby resulting inhe elimination of the source of end-stage biventricular heart failure."

Garippa said: “The partnership with Versa provides SynCardia the resources to continue providing physicians and their patients globally with the life-saving Total Artificial Heart.

“There is greater financial and operational support to grow and flourish nationally and internationally, and to continue development of new and innovative devices.

“Our 70cc TAH-t has dominated the worldwide market, while our newer 50cc device is designed to accommodate underserved populations, including women and adolescents.”

Image: The 70cc SynCardia temporary Total Artificial Heart (TAH-t). Photo: courtesy of SynCardia Systems, Inc.